JEFFREY LAURENCE, M. D.; MORTON COLEMAN, M.D.; STEVEN L. ALLEN, M.D.; RICHARD T. SILVER, M.D.; MARK PASMANTIER, M.D.
A new multiple-drug protocol consisting of cyclophosphamide, vincristine, prednisone, bleomycin, doxorubicin, and procarbazine, known as COP-BLAM, was administered to 48 patients with stage III or IV diffuse histiocytic lymphoma. Twenty-four of the 33 previously untreated patients had a complete remission, and eight patients had a partial response. The median survival for all previously untreated patients has not yet been reached at 23 months. Median survival for complete responders has not yet been attained at 26 months, although survival of partial responders is 12.5 months. There were no patients with a complete response who had a central nervous system relapse. The COP-BLAM therapy is an easily administered outpatient program capable of inducing a high frequency of durable complete remissions in advanced diffuse histiocytic lymphoma, a malignancy formerly considered to have a poor prognosis.
LAURENCE J, COLEMAN M, ALLEN SL, SILVER RT, PASMANTIER M. Combination Chemotherapy of Advanced Diffuse Histiocytic Lymphoma with the Six-Drug COP-BLAM Regimen. Ann Intern Med. ;97:190–195. doi: 10.7326/0003-4819-97-2-190
Download citation file:
Published: Ann Intern Med. 1982;97(2):190-195.
Results provided by:
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use